Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 2, 2002, Pages 306-311

  Tsimihodimos, Vasilis ^a   Karabina, Sonia Athena P ^a   Tambaki, Afroditi P ^a   Bairaktari, Eleni ^a   Goudevenos, John A ^a   Chapman, M John ^a   Elisaf, Moses ^a   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atorvastatin; Hyperlipidemia; Monocytes macrophages; Paraoxonase; Platelet activating factor acetythydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PARAOXON; PHENYLACETIC ACID; PHOSPHOLIPASE A2;

ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, LDL; ESTERASES; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MACROPHAGES; PHOSPHOLIPASES A; PYRROLES;

EID: 0036159510     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq0202.102918     Document Type: Article

References (35)

1. Platelet-activating factor: A mediator for clinicians
2. Platelet-activating factor (PAF): Implications for coronary heart and vascular diseases
3. Platelet-activating factor acetylhydrolases in health and disease
4. Human plasma platelet-activating factor acetylhydrolase: Association with lipoprotein particles and role in the degradation of platelet-activating factor
5. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: Catalytic characteristics and relation to the monocyte-derived enzyme
6. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor
7. Oxidized phospholipids as a new landmark in atherosclerosis
8. Identification of the G994→T missense mutation in exon 9 of the plasma platelet activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men
9. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia
10. 2 in atherogenesis
11. 2 as an independent predictor of coronary heart disease
12. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins
13. HDL, its enzymes and its potential to influence lipid peroxidation
14. Hydrolysis of platelet-activating factor by serum paraoxonase
15. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
16. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low-density lipoprotein
17. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase
18. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
19. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
20. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
21. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients
22. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL
23. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus
24. Human macrophages secrete platelet-activating factor acetylhydrolase
25. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: Effect of hyperinsulinemia and lovastatin treatment
26. Determinants of plasma platelet-activating factor acetylhydrolase: Heritability and relationship to plasma lipoproteins
27. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
28. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma
29. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: Implication for LDL receptor interaction
30. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein
31. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: Effect of c7E3 Fab (abciximab) therapy
32. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids
33. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice
34. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice
35. Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase